corp_html/multi/Profile-antiinfectives1.htm

<p><b>Researching the Fight Against Infection</b></p>
<p>PLIVA's anti-infectives research is being conducted in three separate programs: 
  Macrolide research, New Antibiotics research, and Biodiversity discovery.</p>
<p>With its internationally acknowledged insight into macrolide chemistry, as 
  evidenced by its discovery of Azithromycin, PLIVA has entered into a strategic 
  co-operation with GlaxoWellcome (currently <a
href="http://www.gsk.com">GlaxoSmithKline</a>) to identify a novel macrolide 
  antibiotic for world-wide development and marketing. The goal of this venture 
  is to identify a macrolide with improved efficacy, particularly against resistant 
  strains of bacteria.</p>
<p align="center"><img src="p/OKrnd_ljudi_7.jpg" width="300" height="202" border=1></p>
<p>The goal of PLIVA's second program is to find a novel anti-bacterial compound 
  class showing no cross-resistance with current antibiotics. In cooperation with 
  <a href="http://www.althexis.com">Althexis</a>, Boston, USA, a company with
leading expertise in
structure-based drug 
  design and crystallography, researchers from both companies have identified 
  two novel scaffolds showing activity with <i>in vitro</i> and <i>in vivo</i> 
  models of infections. A derivatization program 
  to identify a developmental candidate within the shortest possible time has 
  been fully established.</p>
<p>As an extension of its anti-bacterial program, PLIVA has licensed-in a novel 
  anti-fungal compound (PLD-118) from <a href="http://www.bayer.com">Bayer
AG</a>, Germany. This compound has demonstrated 
  excellent efficacy against the most common systemic fungal infections as well 
  as excellent tolerability and pharmacokinetic properties in various pre-clinical 
  models. PLD-118 would represent the first novel, orally available compound class 
  for the treatment of infections caused by the Candida yeast since the introduction 
  of the azoles in the 1970s.The project has a novel mode of action and has strong 
  potential to solve azole resistance problems.</p>
<p>In the Biodiversity program, activities are being focused on generating the 
  "toolbox" for the generation of novel enzymes and the application of the technology 
  to streptomyces, one of the most important microbial organisms for the production 
  of small molecules. Significant improvement of the general technology, which 
  is currently patented, has been achieved. The Biodiversity program is conducted 
  in both MIXIS France and PLIVA Zagreb laboratories, and it should give MIXIS 
  a vehicle for future products, a far longer patent protection and simplified 
  and attractive format. </p>
1	dpavlin	1.1	<p><b>Researching the Fight Against Infection</b></p>
2			<p>PLIVA's anti-infectives research is being conducted in three separate programs:
3			Macrolide research, New Antibiotics research, and Biodiversity discovery.</p>
4			<p>With its internationally acknowledged insight into macrolide chemistry, as
5			evidenced by its discovery of Azithromycin, PLIVA has entered into a strategic
6			co-operation with GlaxoWellcome (currently <a
7			href="http://www.gsk.com">GlaxoSmithKline</a>) to identify a novel macrolide
8			antibiotic for world-wide development and marketing. The goal of this venture
9			is to identify a macrolide with improved efficacy, particularly against resistant
10			strains of bacteria.</p>
11			<p align="center"><img src="p/OKrnd_ljudi_7.jpg" width="300" height="202" border=1></p>
12			<p>The goal of PLIVA's second program is to find a novel anti-bacterial compound
13			class showing no cross-resistance with current antibiotics. In cooperation with
14			<a href="http://www.althexis.com">Althexis</a>, Boston, USA, a company with
15			leading expertise in
16			structure-based drug
17			design and crystallography, researchers from both companies have identified
18			two novel scaffolds showing activity with <i>in vitro</i> and <i>in vivo</i>
19			models of infections. A derivatization program
20			to identify a developmental candidate within the shortest possible time has
21			been fully established.</p>
22			<p>As an extension of its anti-bacterial program, PLIVA has licensed-in a novel
23			anti-fungal compound (PLD-118) from <a href="http://www.bayer.com">Bayer
24			AG</a>, Germany. This compound has demonstrated
25			excellent efficacy against the most common systemic fungal infections as well
26			as excellent tolerability and pharmacokinetic properties in various pre-clinical
27			models. PLD-118 would represent the first novel, orally available compound class
28			for the treatment of infections caused by the Candida yeast since the introduction
29			of the azoles in the 1970s.The project has a novel mode of action and has strong
30			potential to solve azole resistance problems.</p>
31			<p>In the Biodiversity program, activities are being focused on generating the
32			"toolbox" for the generation of novel enzymes and the application of the technology
33			to streptomyces, one of the most important microbial organisms for the production
34			of small molecules. Significant improvement of the general technology, which
35			is currently patented, has been achieved. The Biodiversity program is conducted
36			in both MIXIS France and PLIVA Zagreb laboratories, and it should give MIXIS
37			a vehicle for future products, a far longer patent protection and simplified
38			and attractive format. </p>